Роль коррекции гипогонадизма в лечении метаболического синдрома у мужчин

1. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-1607.

2. Anderson P.J., Critchley J.A., Chan J.C., Cockram C.S., Lee Z.S., Thomas G.N., Tomlinson B. Factor analysis of the metabolic syndrome: obesity vs insulin resistance as the central abnormality. Int. J. Obes. Relat. Metab. Disord. 2001;25(12):1782-1788.

3. DeFronzo R.A., Tobin J., Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am. J. Physiol. 1979;237.

4. A new IDF worldwide definition of the metabolic syndrome: the rationale and the results. Diabetes Voice. Vol. 50, Issue 3.

5. Marin P., Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab. 1998 Oct;12(3):441-51.

6. Hu et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004 May 24;164(10):1066-76.

7. Armellini et al. Hormones and body composition in humans: clinical studies. Int J Obes Relat Metab Disord. 2000 Jun;24 Suppl 2:S18-21.

8. Dobs et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab. 2001 Mar;86(3):1026-33.

9. Tsai et al. Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord. 2000 Apr;24(4):485-91.

10. Wang C et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000 Aug;85(8):2839-53.

11. Katznelson et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab. 1996 Dec;81(12):4358-65.

12. Simon et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. J Clin Endocrinol Metab. 1997 Feb;82(2):682-5.

13. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care. 2000 Apr;23(4):490-4.

14. Тhe Rotterdam study, Hak et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002 Aug;87(8):3632-9.).

15. Laaksonen et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol. 2003 Dec;149(6):601-8.

16. Boyanov et al. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003 Mar;6(1):1-7.

17. Marin P. Testosterone and regional fat distribution. Obes Res. 1995 Nov;3(Suppl 4):609S-612S.

18. Makshida et al. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol. 2005 Sep;174(3):827-34.

19. Isidori et al. Effects of testosterone on sexual function in men: results of a meta-analysis.Clin Endocrinol (Oxf). 2005 Oct;63(4):381-94.

20. Дедов И.И., Калинченко С.Ю. Возрастной андрогенный дефицит у мужчин. М.: Практическая медицина, 2006.